The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
After demonstrating significant improvement in progression-free survival, and now overall survival as well, the combination ...
By CH Unnikrsihnan Drug maker and researcher Glenmark Pharmaceuticals Ltd's new biological drug candidate Bi-Specific ...
China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the ...
Strasbourg, France, January 23, 2026, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced th ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...
Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.
Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results